SLC5A2 and hydrops fetalis: Moreover, previous meta‐analyses of SGLT2 inhibitors have not specifically focused on patients with prevalent HF across all trials, and none of the studies have included results from the recently published SOLOIST‐WHF trial.9, 10, 11, 12, 13